Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Senior Vice Health Minister, Parliamentary Secretary Test Negative for Coronavirus
March 3, 2020
- MHLW Panel Clears Latuda, 1st Japan-Originated Oligonucleotide; Approval Expected in March
March 2, 2020
- Daiichi Sankyo’s Enhertu Clears MHLW Panel, Conditional Nod Expected in March
February 27, 2020
- Rust in Needles in Sanofi’s ActHIB “Occurred Accidentally,” Supplies to Resume: MHLW
February 27, 2020
- Zolgensma Now in Line for Japan Approval in March, All Eyes Now Riveted on Price
February 27, 2020
- MHLW Orders Label Revisions for 9 Hep C Drugs
February 26, 2020
- Japan Plans to Reimburse Coronavirus Tests: Health Minister
February 26, 2020
- Japan Adopts Basic Plan against Novel Coronavirus
February 26, 2020
- Japan Approves Label Expansions for Rozlytrek, Alecensa and More
February 25, 2020
- MHLW Has to Decide Which Bureau Will Lead Formulary Push: Pharmacy Officer
February 21, 2020
- AMED to Fund Development of Coronavirus Diagnostics, Treatments, and Vaccines by NIID, Univ. of Tokyo
February 21, 2020
- Japan Panel to Review J-TEC’s Cell Product, Zolgensma on Feb. 26; Orphan Status for Luxturna Also Up for Discussion
February 20, 2020
- MHLW Looking to Build an “Integrated Pre- to Post-Marketing Assessment System”: Safety Division Chief
February 20, 2020
- MHLW Panel Backs Approval of Sakigake-Designated BNCT Radiation Therapy System
February 20, 2020
- 6 APIs Including Inebilizumab Designated as Orphan Drugs: MHLW
February 19, 2020
- Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
- MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
- Japan OKs Edirol Generics towards June Listing, First Gx Entries for 13 Other Drugs Too
February 17, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…